Piper Sandler Downgrades Tango Therapeutics to Neutral, Raises Price Target to $24
Benzinga Newsdesk 5 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Piper Sandler analyst Kelsey Goodwin downgrades Tango Therapeutics (NASDAQ:TNGX) from Overweight to Neutral and raises the price target from $16 to $24.
Piper Sandler analyst Kelsey Goodwin downgrades Tango Therapeutics (NASDAQ:TNGX) from Overweight to Neutral and raises the price target from $16 to $24.